# GSK plc: Form 13F holdings

An institutional investment manager in London. SEC CIK 1131399.

- Quarter ended: 2026-06-30
- Filed: 2026-08-13
- Reported value: $602.2m
- Positions: 13 (13 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1131399/000199937126017873/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| CRISPR THERAPEUTICS AG | NAMEN AKT | $175.7m | 29.2% | 3,220,627 |  | Unchanged |
| WAVE LIFE SCIENCES LTD | SHS | $106.0m | 17.6% | 18,245,691 |  | Unchanged |
| [VIR BIOTECHNOLOGY INC (VIR)](/companies/vir.md) | COM | $87.1m | 14.5% | 8,550,954 |  | Unchanged |
| [BIONTECH SE (BNTX)](/companies/bntx.md) | SPONSORED ADS | $82.8m | 13.7% | 889,824 |  | Unchanged |
| [IDEAYA BIOSCIENCES INC (IDYA)](/companies/idya.md) | COM | $49.7m | 8.3% | 1,333,333 |  | Unchanged |
| [CYTOKINETICS INC (CYTK)](/companies/cytk.md) | COM NEW | $29.0m | 4.8% | 340,434 |  | Unchanged |
| [LYELL IMMUNOPHARMA INC (LYEL)](/companies/lyel.md) | COM NEW | $21.3m | 3.5% | 1,512,659 |  | Unchanged |
| [SPERO THERAPEUTICS INC (SPRO)](/companies/spro.md) | COM | $20.3m | 3.4% | 9,190,606 |  | Unchanged |
| [NKARTA INC (NKTX)](/companies/nktx.md) | COM | $8.9m | 1.5% | 3,150,732 |  | Unchanged |
| [FULCRUM THERAPEUTICS INC (FULC)](/companies/fulc.md) | COM | $6.5m | 1.1% | 1,785,714 |  | Unchanged |
| [BICYCLE THERAPEUTICS PLC (BCYC)](/companies/bcyc.md) | SPONSORED ADS | $6.5m | 1.1% | 1,529,561 |  | Unchanged |
| [CVRX INC (CVRX)](/companies/cvrx.md) | COM | $5.2m | 0.9% | 1,007,583 |  | Unchanged |
| [REGENXBIO INC (RGNX)](/companies/rgnx.md) | COM | $3.3m | 0.5% | 271,456 |  | Unchanged |

Source: SEC EDGAR, Form 13F-HR, accession 0001999371-26-017873. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.